Quito-based Takeda Ecuador will carry out sales and marketing operations of the company’s products in the region.
Carlos Haro who previously served as general manager for Sanofi, is named as the new country manager for Ecuador.
Takeda Latin America senior vice president Norbert Oppitz said the launch of Ecuador subsidiary will help meeting diverse healthcare needs of the patient population.
"We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market," Oppitz added.
"This investment further demonstrates our commitment to Latin America and its growth potential. We have ambitious plans in this region and we continue to evaluate opportunities to expand our footprint."
Products related to gastroenterology, cardiology, metabolism, oncology and respiratory diseases will be commercialized by the new subsidiary.
The initial focus will be on Zurcal (pantoprazole), Faktu (Policresulen, Cinchocaine hydrochloride), Alevian Duo (Pinaverium bromide, Dimeticone) and Tecta (pantoprazole magnesium) and Albothyl (Policresulen).